Intuitive Surgical Analyst Ratings
Citi Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $560
RBC Capital Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $515
RBC Capital Reaffirms Their Buy Rating on Intuitive Surgical (ISRG)
Intuitive Surgical Price Target Raised to $510.00/Share From $380.00 by Redburn Atlantic
Intuitive Surgical Analyst Ratings
Redburn Upgrades Intuitive Surgical to Buy, Cites Updated Guidance
Redburn Atlantic Upgrades Intuitive Surgical(ISRG.US) to Buy Rating, Announces Target Price $510
Redburn Atlantic Upgrades Intuitive Surgical to Buy From Neutral, Adjusts Price Target to $510 From $380
Daiwa Securities Adjusts Price Target on Intuitive Surgical to $460 From $430
Intuitive Surgical Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Intuitive Surgical (ISRG)
Barclays Adjusts Price Target on Intuitive Surgical to $510 From $490
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
Baird Maintains Outperform on Intuitive Surgical, Raises Price Target to $503
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
Morgan Stanley Adjusts Price Target on Intuitive Surgical to $475 From $460, Maintains Equalweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
No Data